Antony Farias, MD
Nephrology · Miami, FLNPI 1891022141
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Vifor Pharma, Inc. at 40.8% of the total. Reporting peaked in 2019 at $2,554 and has fallen 55.9% since, to $1,126 in 2025. Among nephrology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $49.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$3K
- AstraZeneca$961
- Novo Nordisk AS$625
- Aurinia Pharma U.S., Inc.$581
- Fresenius USA Marketing, Inc.$380
- Ardelyx, Inc.$269
- plus $2K from 19 others
Across 159 payments — averaging $254.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$40K
What the payments were for
- Speaking & faculty fees$3,30039%
- Travel & lodging$2253%
- Food & beverage$4,68656%
- Education$1902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 5 | $3,428 |
| AstraZeneca | 42 | $961 |
| Novo Nordisk AS | 2 | $625 |
| Aurinia Pharma U.S., Inc. | 18 | $581 |
| Fresenius USA Marketing, Inc. | 20 | $380 |
| Ardelyx, Inc. | 12 | $269 |
| Calliditas Therapeutics US Inc. | 10 | $268 |
| Novo Nordisk | 10 | $268 |
| Bayer | 13 | $258 |
| Nxstage Medical, Inc. | 2 | $240 |
| Otsuka America Pharmaceutical, Inc. | 7 | $208 |
| Amgen(2 entities) | 6 | $154 |
| GSK | 2 | $144 |
| Metuchen Pharmaceuticals | 1 | $119 |
| Mallinckrodt Hospital Products Inc. | 4 | $90 |
| Boehringer Ingelheim | 2 | $62 |
| Medtronic | 1 | $59 |
| Akebia Therapeutics Inc | 2 | $50 |
| Cycle Pharmaceuticals Inc | 2 | $50 |
| Novartis | 2 | $46 |
| Travere Therapeutics, Inc. | 4 | $42 |
| Scpharmaceuticals Inc. | 1 | $35 |
| Surmodics, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Cormedix Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$3,406
- NXSTAGE SYSTEM ONE$240
- LUPKYNIS$232
- NXSTAGE CARTRIDGE EXPRESS$129
- TARPEYO$126
- FARXIGA$124
- Ozempic$120
- BENLYSTA$119
- Stendra$119
How this compares
$8,400 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 258 | $219,832 |
| KerendiaFinerenone | 123 | $99,574 |
| JardianceEmpagliflozin | 78 | $50,968 |
| VeltassaPatiromer Calcium Sorbitex | 33 | $35,979 |
| LokelmaSodium Zirconium Cyclosilicate | 42 | $28,483 |
| RetacritEpoetin Alfa-Epbx | 90 | $24,573 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $16,737 |
| ProcritEpoetin Alfa | 13 | $9,299 |
| EntrestoSacubitril/Valsartan | 11 | $8,041 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,620 |
| Telmisartan | 256 | $4,711 |
| Sevelamer Carbonate | 24 | $3,499 |
| EdarbiAzilsartan Medoxomil | 11 | $2,635 |
| Torsemide | 104 | $2,092 |
| Nifedipine ErNifedipine | 64 | $1,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $961 | $248,315300 claims |
| BayerKerendia | $258 | $99,574123 claims |
| Boehringer IngelheimJardiance | $62 | $50,96878 claims |
| NovartisEntresto | $46 | $8,04111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.
Other nephrology in Miami
- Gabriel ContrerasMiami$133K
- Alessia FornoniMiami$97K
- Jonathan da CostaMiami$74K
- Yelena DrexlerMiami$43K
- Jochen ReiserMiami$43K
- Alba Gonzalez-OchoaMiami$39K
- Jorge BusseMiami$28K
- Loay SalmanMiami$14K
- David RothMiami$12K
- Arvind MadanOrlando$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.